Despite the promising therapeutic potential of CD44 as a tumor target, the side effects of targeting CD44, such as severe skin toxicity, are the greatest obstacles to clinical treatment due to the wide and high-level expression of CD44 in normal tissues. This evidence concerns the gene CD44 and neoplasm.